VIVIMED LABS LIMITED (VIVIMEDLAB) financials

VIVIMED LABS LIMITED (VIVIMEDLAB) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.[1][2]

Market Cap: ₹54.6Cr.
Current Price: ₹6.58
ROE: %
ROCE: -47.3%
Book Value: ₹-13.5
Dividend Yield: 0.00%
52W High / Low: ₹29.4/4.75

In Mar 2026, VIVIMED LABS LIMITED (VIVIMEDLAB) reported sales ₹8 Cr and net profit ₹-142 Cr.

Annual Mar 2026: sales ₹56 Cr, net profit ₹-172 Cr.

Shareholding: Promoters 7.57% (Mar 2026), FIIs 1.64% (Mar 2026), Government 0.12% (Mar 2026), Public 90.66% (Mar 2026), No. of Shareholders 47,492% (Mar 2026).

VIVIMEDLAB quarterly results (₹ Cr.)
Category	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	25	22	34	23	18	19	12	8
Expenses	36	23	34	25	18	20	23	145
Operating Profit	-11	-1	-0	-2	-1	-1	-11	-137
OPM %	-45%	-3.6%	-0.5%	-11%	-3.0%	-7%	-96%	-1,815%
Other Income	0	0	0	4	0	0	0	0
Interest	0	0	0	1	1	2	1	1
Depreciation	4	4	6	5	5	5	4	4
Profit before tax	-15	-5	-7	-4	-6	-7	-17	-142
Tax %	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	-15	-5	-7	-4	-6	-7	-17	-142
EPS in Rs	-1.82	-0.60	-0.84	-0.53	-0.66	-0.90	-2.00	-17.14
Raw PDF	—	—	—	—	—	—	—	—

VIVIMEDLAB profit and loss (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	252	277	210	218	177	137	104	56
Expenses	184	237	182	227	365	170	118	206
Operating Profit	67	40	28	-9	-188	-33	-15	-150
OPM %	27%	14%	13%	-4.1%	-106%	-24%	-14%	-269%
Other Income	9	-0	6	1	0	10	4	1
Interest	53	43	42	40	36	2	3	4
Depreciation	18	17	16	17	107	18	19	18
Profit before tax	5	-21	-24	-65	-330	-44	-32	-172
Tax %	-20%	-8%	-1%	4%	-1%	0%	0%	0%
Net Profit	6	-19	-23	-68	-328	-44	-32	-172
EPS in Rs	0.75	-2.31	-2.81	-8.17	-39.56	-5.35	-3.80	-20.70
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%

VIVIMEDLAB balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	17	17	17	17	17	17	17	17
Reserves	556	537	508	441	117	73	42	-129
Borrowings	348	304	323	357	377	375	375	388
Other Liabilities	234	210	247	258	286	217	206	226
Total Liabilities	1,155	1,067	1,095	1,072	796	681	639	502
Fixed Assets	381	356	416	429	343	326	315	286
CWIP	64	70	58	40	21	21	17	17
Investments	88	88	161	161	161	59	59	56
Other Assets	622	554	459	442	271	276	248	142
Total Assets	1,155	1,067	1,095	1,072	796	681	639	502

VIVIMEDLAB cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	82	75	180	25	33	-97	6	4
Cash from Investing Activity	56	3	-138	-11	-2	100	-4	-0
Cash from Financing Activity	-123	-91	-46	-13	-35	-6	-3	-5
Net Cash Flow	15	-13	-5	1	-3	-2	-1	-0
Free Cash Flow	66	78	115	14	31	-99	2	4
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	160%	205%	654%	-280%	-17%	291%	-39%	-3%

VIVIMEDLAB shareholding pattern (%)
Category	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	20.94%	20.94%	20.94%	20.94%	7.76%	7.76%	7.76%	7.57%
FIIs	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%
Government	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
Public	77.30%	77.30%	77.30%	77.30%	90.47%	90.47%	90.47%	90.66%
No. of Shareholders	49,012	49,003	49,005	48,957	48,928	48,925	49,221	47,492

VIVIMEDLAB key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	148	118	133	106	104	159	161	284
Inventory Days	1,284	640	954	608	106	340	354	56
Days Payable	160	75	124	95	77	211	211	266
Cash Conversion Cycle	1,271	683	963	619	134	289	304	73
Working Capital Days	375	319	213	116	-299	-311	-513	-1,828
ROCE %	6%	3%	2%	-3%	-44%	-9%	-6%	-47%

VIVIMEDLABUpdated 17 Oct 2026, 9:40

Vivimed Labs Limited

VIVIMEDLABUpdated 17 Oct 2026, 9:40

Market Cap

₹54.6Cr.

Current Price

₹6.58

High / Low

₹29.4/4.75

ROE%

ROCE-47.3%

Book Value₹-13.5

Face Value₹2.00

Dividend Yield0.00%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2023	40	8	203	0	95	-267	-1	-265	-31.94
Jun 2023	33	11	33	0	4	-15	0	-15	-1.85
Sep 2023	30	12	36	2	4	-20	0	-20	-2.36
Dec 2023	37	13	36	0	4	-17	-3	-16	-1.95
Mar 2024	36	-34	65	7	5	7	24	6	0.66
Jun 2024	25	0	36	0	4	-15	0	-15	-1.82
Sep 2024	22	0	23	0	4	-5	0	-5	-0.6
Dec 2024	34	0	34	0	6	-7	0	-7	-0.84
Mar 2025	23	1	25	4	5	-4	0	-4	-0.53
Jun 2025	18	1	18	0	5	-6	0	-6	-0.66
Sep 2025	19	2	20	0	5	-7	0	-7	-0.9
Dec 2025	12	1	23	0	4	-17	0	-17	-2
Mar 2026	8	1	145	0	4	-142	0	-142	-17.14

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	430	64	323	1	21	24	22	19	2.34
Mar 2016	319	57	233	1	19	11	28	8	1
Mar 2017	570	59	319	9	27	173	27	126	15.59
Mar 2018	261	53	183	2	18	9	-12	10	1.2
Mar 2019	252	53	184	9	18	5	-20	6	0.75
Mar 2020	277	43	237	0	17	-21	-8	-19	-2.31
Mar 2021	210	42	182	6	16	-24	-1	-23	-2.81
Mar 2022	218	40	227	1	17	-65	4	-68	-8.17
Mar 2023	177	36	365	0	107	-330	-1	-328	-39.56
Mar 2024	137	2	170	10	18	-44	0	-44	-5.35
Mar 2025	104	3	118	4	19	-32	0	-32	-3.8
Mar 2026	56	4	206	1	18	-172	0	-172	-20.7

Shareholding pattern

As of Mar 2026%

Holder	Share
Promoters	7.57%
FIIs	1.64%
Government	0.12%
Public	90.66%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Jun 2023	20.94%	1.64%	—	0.12%	77.3%
Sep 2023	20.94%	1.64%	—	0.12%	77.29%
Dec 2023	20.94%	1.64%	—	0.12%	77.3%
Mar 2024	20.94%	1.64%	—	0.12%	77.29%
Jun 2024	20.94%	1.64%	—	0.12%	77.3%
Sep 2024	20.94%	1.64%	—	0.12%	77.3%
Dec 2024	20.94%	1.64%	—	0.12%	77.3%
Mar 2025	20.94%	1.64%	—	0.12%	77.3%
Jun 2025	7.76%	1.64%	—	0.12%	90.47%
Sep 2025	7.76%	1.64%	—	0.12%	90.47%
Dec 2025	7.76%	1.64%	—	0.12%	90.47%
Mar 2026	7.57%	1.64%	—	0.12%	90.66%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	16	358	698	231	1303	377	63	230	633	1303
Mar 2016	16	353	599	397	1365	387	41	230	708	1365
Mar 2017	16	545	571	229	1361	433	59	88	781	1361
Mar 2018	17	551	446	243	1255	405	43	152	656	1255
Mar 2019	17	556	348	234	1155	381	64	88	622	1155
Mar 2020	17	537	304	210	1067	356	70	88	554	1067
Mar 2021	17	508	323	247	1095	416	58	161	459	1095
Mar 2022	17	441	357	258	1072	429	40	161	442	1072
Mar 2023	17	117	377	286	796	343	21	161	271	796
Mar 2024	17	73	375	217	681	326	21	59	276	681
Mar 2025	17	42	375	206	639	315	17	59	248	639
Mar 2026	17	-129	388	226	502	286	17	56	142	502

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	41	-50	9	1
Mar 2016	-54	-11	59	-7
Mar 2017	28	30	-50	8
Mar 2018	207	-38	-175	-6
Mar 2019	82	56	-123	15
Mar 2020	75	3	-91	-13
Mar 2021	180	-138	-46	-5
Mar 2022	25	-11	-13	1
Mar 2023	33	-2	-35	-3
Mar 2024	-97	100	-6	-2
Mar 2025	6	-4	-3	-1
Mar 2026	4	0	-5	0

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	194	264	144	234	148	118	133	106	104	159	161	284
Inventory Days	410	744	579	1,236	1,284	640	954	608	106	340	354	56
Days Payable	84	68	92	99	160	75	124	95	77	211	211	266
Cash Conversion Cycle	520	940	632	1,371	1,271	683	963	619	134	289	304	73
Working Capital Days	132	291	168	345	375	319	213	116	-299	-311	-513	-1,828
ROCE %	8%	7%	22%	6%	6%	3%	2%	-3%	-44%	-9%	-6%	-47%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of VIVIMED LABS LIMITED (VIVIMEDLAB)?

The reported market capitalisation for VIVIMED LABS LIMITED (VIVIMEDLAB) is ₹54.6Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of VIVIMEDLAB?

The current price shown for VIVIMED LABS LIMITED (VIVIMEDLAB) on Fincrux is ₹6.58 with a 52-week high/low of ₹29.4/4.75.

What were VIVIMEDLAB latest quarterly results?

For Mar 2026, VIVIMED LABS LIMITED (VIVIMEDLAB) reported sales ₹8 Cr and net profit ₹-142 Cr (figures in ₹ crore unless noted).

What are VIVIMEDLAB annual sales and net profit?

For Mar 2026, VIVIMED LABS LIMITED (VIVIMEDLAB) shows sales of ₹56 Cr and net profit of ₹-172 Cr on the Fincrux profit & loss statement.

Who owns VIVIMED LABS LIMITED (VIVIMEDLAB)?

Latest shareholding for VIVIMED LABS LIMITED (VIVIMEDLAB) on Fincrux: Promoters 7.57% (Mar 2026), FIIs 1.64% (Mar 2026), Government 0.12% (Mar 2026), Public 90.66% (Mar 2026), No. of Shareholders 47,492% (Mar 2026).

Where can I find VIVIMED LABS LIMITED (VIVIMEDLAB) financials?

VIVIMED LABS LIMITED (VIVIMEDLAB) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show VIVIMEDLAB balance sheet and cash flow?

Yes. The VIVIMED LABS LIMITED (VIVIMEDLAB) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 17 October 2026 at 9:40